Efficacy of simvastatin in plaque psoriasis: A pilot study

Shirinsky, I.; Shirinsky, V.

doi:10.1016/j.jaad.2007.05.040

Cited by 73 publications

(63 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, it was discovered that statins possess an immunomodulatory activity by supporting a Th1/Th2 skew to Th1, altering lymphocyte migration, inhibition of MHC-II induction and cytokine release on antigen-presenting cells, inhibition of mast cell degranulation and inhibition of Th17 cells and IL-17 production [22,23]. There was one pilot study performed by Shirinsky et al in which statins was used specifically for the treatment of psoriasis [24]. At the end of 8 weeks of the treatment with simvastatin 40 mg/d, the researchers found a statistically significant decrease in the mean PASI score.…”

Section: Discussionmentioning

confidence: 99%

Eruption of palmoplantar pustular psoriasis in patient treated with anti-androgen therapy for prostate cancer and aggravation of lesions after statin treatment

et al. 2014

View full text Add to dashboard Cite

AbstractThe article focuses on the eruption of palmoplantar pustular psoriasis, which was documented in a 53-year-old man diagnosed with prostate cancer with bone metastases. This clinical finding was made during routine hormone therapy and palliative radiotherapy. The local improvement in skin lesions was achieved following administration of topical ointments and the use of UVA 311 nm radiation therapy. The management of prostate cancer in this subject resulted in malaise, onset of diabetes mellitus and increased concentration of serum lipids. Interestingly, a few days after the statin treatment was initiated, the intensive pustule eruption was observed as well as severe pain and burning sensation in the palms and soles. The dermatological treatment led to significant improvement. The patient is still receiving oncological therapy and is monitored by dermatologists on a regular basis.

show abstract

Section: Discussionmentioning

confidence: 99%

Eruption of palmoplantar pustular psoriasis in patient treated with anti-androgen therapy for prostate cancer and aggravation of lesions after statin treatment

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Statins may exacerbate or improve psoriasis 32,33 . A study of simvastatin showed significant reduction in PASI scores (47.34%) 34 .…”

Section: Dyslipidemiamentioning

confidence: 99%

Comorbidities in psoriasis: The recognition of psoriasis as a systemic disease and current management

Kalkan¹

2017

TURKDERM

View full text Add to dashboard Cite

©Copyright 2017 by Turkish Society of Dermatology and Venereology Turkderm-Turkish Archives of Dermatology and Venereology published by Galenos Yayınevi. Öz IntroductionPsoriasis, with a worldwide prevalence of 2-3%, is now assumed as a systemic chronic inflammatory disease accompanied by comorbidities while it was accepted as a disease limited only to the skin in the past 1 . Psoriasis and its comorbidities were the main focused topic at several sessions of the 73 rd Annual Meeting of the American Academy of Dermatology and, especially, systemic disease concept was emphasized 2 . Therefore, recent publications suggest that the term psoriatic disease would be a better nomination instead of psoriasis 3 . In this review, learning screening recommendations developed for early detection and treatment of comorbidities as well as integrated, multidisciplinary approach for disease management have been targeted by reviewing psoriasis and accompanying comorbidities. Comorbidities are more frequently seen in 15% of psoriasis patients who have moderate to severe psoriasis due to increased inflammatory impact and common pathogenesis. Consistent monitoring and systemic treatment are required to prevent development of comorbidities. There are several Tüm dünyada %2-3 oranında görülme sıklığına sahip psoriazis, geçmişte sadece deriye sınırlı kabul edilirken, günümüzde birçok komorbiditenin eşlik ettiği kronik sistemik enflamatuvar bir hastalık olarak ele alınmaktadır. Orta-şiddetli düzeyde psoriazisi olanlarda daha sık görülen komorbiditelerle ilgili çeşitli sınıflamalar mevcuttur. Basit olarak klasik, kronik sistemik enflamasyonla ilişkili, yaşam tarzı ile ilgili ve tedavi ile ilgili olarak sınıflanabileceği gibi medikal komorbiditeler, psikiyatrik/psikolojik komorbiditeler ve komorbiditelere katkı yapan durumlar şeklinde de sınıflanabilmektedir. Bu derlemede psoriazis ve eşlik eden komorbiditelerin gözden geçirilmesiyle; komorbiditelerin erken tanı ve tedavisini sağlama, komorbiditilerin erken tespitine yönelik geliştirilen tarama önerilerini öğrenme ve hastalığın yönetiminde entegre, multidisipliner yaklaşım ile uzun dönem hastalık kontrolü ve hayat kalitesinde düzelme sağlamak hedeflenmektedir. Anahtar Kelimeler: Psoriazis, komorbidite, sistemik hastalık Psoriasis, with a worldwide prevalence of 2-3%, is now assumed as a systemic chronic inflammatory disease accompanied by comorbidities while it was accepted as a disease limited only to the skin in the past. There are several classifications of the comorbidities which are more common in patients with moderate to severe psoriasis. Simply, comorbidities can be classified as classic, emerging, related to lifestyle, related to treatment. They can also be categorized as medical comorbidities, psychiatric/psychologic comorbidities, and behaviors contributing to medical and psychiatric comorbidities. In this review, providing early diagnosis and treatment of comorbidities, learning screening recommendations for early detection and long-term disease control and improvemen...

show abstract

“…Таким образом, при синтропных заболева-ниях возможна альтернатива полипрагмазии [29], агонистов PPARα у больных эро-зивным остеоартритом [28]. Правомочность выбранной стратегии лече-ния синтропных коморбидных заболеваний под-тверждается результатами настоящего исследова-ния.…”

Section: таблица 2 лабораторные показатели до и после терапии фенофиunclassified

Clinical Efficacy and Safety of Peroxisome Proliferator-Activated Receptor Alpha Agonists in Rheumatoid Arthritis: An Open-Label Controlled Study

et al. 2014

View full text Add to dashboard Cite

Адрес для переписки:Ширинский Иван Валерьевич д.м.н., ведущий научный сотрудник лаборатории клинической иммунофармакологии ФГБУ «НИИ клинической иммунологии» СО РАМН 630047, Россия, г. Новосибирск, ул. Залесского, 6. Тел.: 8 (383) 228-25-47. Факс: 8 (383) 228-25-47. E-mail: ishirinsky@mail ФГБУ «НИИ клинической иммунологии» СО РАМН, г. Новосибирск, РоссияРезюме. В контролируемом исследовании изучалась эффективность применения агониста PPARα (фенофибрата), его фармакодинамика у больных ревматоидным артритом, получавших стандарт-ные DMARD. После 12 недель лечения в опытной группе (33 больных) в сравнении с контрольной группой (17 больных) зарегистрировано статистически значимое снижение интегрального показате-ля активности DAS28 и его составляющих: числа болезненных и припухших суставов, СОЭ. Частота EULAR и ACR20 ответов в опытной группе в 4 раза превышала частоту в контрольной группе больных. Клинический эффект был сопряжен со снижением иммунологических маркеров атеросклероза (IL-6 и СРБ), уменьшением общего уровня холестерина и триглицеридов в сыворотке крови. Заключается, что агонисты PPARα являются примером «узловой» терапии ревматоидного артрита с плейотропным действием и направленной на снижение активности воспаления и риска развития коморбидной па-тологии -атеросклероза. Оригинальные статьиOriginal articles Медицинская иммунология 2014, Т. 16, № 1, стр. 71-80 © 2014, СПб РО РААКИ Medical Immunology 2014, Vol. 16, 1, pp. 71-80 © 2014 Abstract. Efficacy and pharmacodynamics of PPARα agonist fenofibrate have been assessed in a controlled study on patients with active rheumatoid arthritis (RA) receiving traditional DMARDs. After 12 weeks of treatment, we observed a significant drop of DAS28 scores, decrease in number of tender and swollen joints, and slower ESR in fenofibrate group (n = 33) as compared with control group (n = 17). Frequency of EULAR and ACR20 responses was 4 times higher in fenofibrate group. Clinical effect was accompanied by decrease in serum immunological markers of atherosclerosis (IL-6 and CRP), diminished total cholesterol and triglycerides. In summary, PPARα agonists may represent an example of a "hub" treatment for rheumatoid arthritis, with pleiotropic effects directed at inflammatory activity and increased risk of other comorbidites, including atherosclerosis. CLINICAL EFFICACY AND SAFETY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR

show abstract

Efficacy of simvastatin in plaque psoriasis: A pilot study

Cited by 73 publications

References 5 publications

Eruption of palmoplantar pustular psoriasis in patient treated with anti-androgen therapy for prostate cancer and aggravation of lesions after statin treatment

Eruption of palmoplantar pustular psoriasis in patient treated with anti-androgen therapy for prostate cancer and aggravation of lesions after statin treatment

Comorbidities in psoriasis: The recognition of psoriasis as a systemic disease and current management

Clinical Efficacy and Safety of Peroxisome Proliferator-Activated Receptor Alpha Agonists in Rheumatoid Arthritis: An Open-Label Controlled Study

Contact Info

Product

Resources

About